OverviewChartNewsTraderScreen

Obseva SA/  CH1260041939  /

Nasdaq Other OTC
2023-04-24  9:51:22 PM Chg. - Volume Bid2023-03-23 Ask2023-03-23 High Low
0.0840USD - 127,403
Turnover: 11,030.1059		 0.0824Bid Size: 900 0.0847Ask Size: 5,200 0.0980 0.0800
GlobeNewswire 04-03 ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated...
GlobeNewswire 03-19 ObsEva Announces Update on Board of Directors
GlobeNewswire 03-08 XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming ...
GlobeNewswire 02-28 ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establi...
GlobeNewswire 01-31 Geneva Court Grants Temporary Moratorium to ObsEva
GlobeNewswire 2023-11-30 ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
GlobeNewswire 2023-11-07 XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive S...
GlobeNewswire 2023-10-27 Organon Returns Ebopiprant to XOMA
GlobeNewswire 2023-09-27 ObsEva Files half Year 2023 Financial Statements
GlobeNewswire 2022-03-22 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire 2022-03-22 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire 2022-03-10 ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
GlobeNewswire 2022-02-10 ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
GlobeNewswire 2022-02-04 ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist...
GlobeNewswire 2022-02-01 ObsEva Appoints Katja Buhrer as Chief Strategy Officer
GlobeNewswire 2022-01-28 ObsEva Announces Corporate Updates
GlobeNewswire 2022-01-06 ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3...
GlobeNewswire 2022-01-05 Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWa...
GlobeNewswire 2022-01-03 ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
GlobeNewswire 2021-12-17 ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of...
GlobeNewswire 2021-12-13 ObsEva Appoints Will Brown as Chief Financial Officer
GlobeNewswire 2021-12-11 Annual Changes to the Nasdaq Biotechnology Index
GlobeNewswire 2021-12-10 ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congres...
GlobeNewswire 2021-12-02 ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at S...
GlobeNewswire 2021-11-29 Rapid7 Appoints Tim Adams as Chief Financial Officer